Zepzelca

Chemical Namelurbinectedin
Dosage FormInjection (intravenous; 4 mg)
Drug ClassAlkylating agents
SystemRespiratory
CompanyPharma Mar
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zepzelca (lurbinectedin) Prescribing Information.2020Jazz Pharmaceuticals, Inc. Palo Alto, CA
Document TitleYearSource
SEOM clinical guidelines for the treatment of small‑cell lung cancer (SCLC) (2019).2020Clinical and Translational Oncology